

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and
additions by underlining)

What is claimed is:

1-6. (canceled)

7 (previously amended): A compound wherein said compound is

[D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]-GLP-1(7-34)NH₂;
[D-Ala^{8,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂;
[Ala^{18,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 83);
[Ala^{16,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 84);
[Ala^{14,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 85);
[Ala^{22,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 86);
[Hppa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 87);
[Ala^{15,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 88);
[Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 89);
[Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 90);
[Ala^{15,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 91);
[Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 92);
[Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 93);
[Ala^{21,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 94);
[Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 95);
[Ala^{22,23,27,32}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 96);
[Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 97);
[Ala^{22,23,27,31}, 3-Pal¹⁹, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 98);
[Ala^{22,23,27,28}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 99);
[Ala^{22,23,27,29}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 100);
[Ala^{23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 101);
[Ala^{20,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO:
102);
[Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 103);
[Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO:
104);
[D-Ala¹⁰, Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂;

[D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂;
[Ala^{17,23,27}, 3-Pal^{19,26,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 105);
[D-Ala⁸, Ala¹⁷, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂;
[Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 106);
[D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle²⁹]hGLP-1(7-34)-NH₂;
[D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle¹⁶]hGLP-1(7-34)-NH₂;
[D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
[D-Ala²², Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
[Aib⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 107);
[D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂;
[Aib⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 108);
[Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 109);
[Ala^{17,23,27}, 3-Pal^{19,31}, Tle³³, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 110);
[Tle¹⁶, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 111);
[N-Me-D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂;
[Aib⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 112);
[Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle^{16,20}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 113);
[D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle¹⁶, Gaba³⁴]hGLP-1(7-34)-NH₂;
[D-Ala^{8,22}, Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
[D-Ala^{8,18}, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
[D-Ala^{8,17}, Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or
[D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or a pharmaceutically acceptable salt thereof.

8-9 (canceled)

10 (previously amended): A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an

effective amount of a compound according to claim 7 or a pharmaceutically acceptable salt thereof.

11 (currently amended) : A method of treating a ~~disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension,~~ in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 7 or a pharmaceutically acceptable salt thereof.

12 (canceled)